Skip to main content
. 2022 Jan 28;27(3):914. doi: 10.3390/molecules27030914

Figure 9.

Figure 9

Effect of “in vivo” EAm and PEm treatments on the content of CD45 and of the glial fibrillar astrocytic protein (GFAP) in EAE mouse spinal-cord homogenates. (a) Representative Western blot of the immunostainings for CD45, GFAP and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in untreated, EAm-treated and PEm-treated EAE mouse spinal-cord homogenates. The protein GAPDH was used as the internal control. The blot is representative of the analysis on lysates from 6 animals for each experimental group. (b) Quantification of the change of CD45 density in the spinal-cord homogenates of EAm-treated (n = 6 mice) and PEm-treated (n = 6 mice) EAE mice versus the untreated ones (n = 6). Results are calculated as CD45 ÷ GAPDH ratio and are expressed as percentage of the respective ratio in untreated EAE mice (1.12 ± 0.22). Data are expressed as mean ± SEM. (c). Quantification of the change of GFAP density in the spinal cord homogenates of EAm-treated (n = 6 mice) and PEm-treated (n = 6 mice) EAE mice versus that of untreated ones (n = 6). Results are calculated as GFAP ÷ GAPDH ratio and are expressed as percentage of the respective ratio in untreated EAE mice (3.52 ± 0.41). Data are expressed as mean ± SEM. Note: * p < 0.05 versus untreated EAE mice; ** p < 0.01 versus untreated EAE mice. EA and PEm administration did not cause significant changes in the expression of the CD45 and the GFAP protein densities in control mice.